Columbia Laboratories Licenses STRIANT Canadian Trademark and Marketing Rights to Invaron Pharmaceuticals Inc.

Columbia Laboratories, Inc. CBRX has entered into a license agreement with Invaron Pharmaceuticals Inc., a privately-held Canadian pharmaceutical company, for STRIANT in Canada. Under the terms of the agreement, Invaron will seek regulatory approval for and will market STRIANT in Canada. Columbia will receive a royalty on annual net sales of STRIANT in Canada, assuming Invaron receives Health Canada regulatory approval. Revenues to Columbia are not expected to be material.